10-Q: Day One Biopharma Q3 2025: OJEMDA Sales Surge, Losses Mount

Day One Biopharmaceuticals reports significant product revenue growth for OJEMDA in Q3 2025, alongside increased net losses and strategic program adjustments.

Summary

• Net loss for the three months ended September 30, 2025, was $(19.7) million, compared to net income of $37.0 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $(86.0) million, compared to a net loss of $(29.8) million for the same period in 2024.
• Product revenue, net, increased by 91.9% to $38.5 million for Q3 2025, from $20.1 million in Q3 2024.
• Product revenue, net, increased by 263.0% to $102.6 million for the nine months ended September 30, 2025, from $28.3 million in the prior year period.
• License revenue decreased significantly to $1.3 million in Q3 2025 from $73.7 million in Q3 2024, primarily due to the non-recurrence of a large upfront payment from the Ipsen License Agreement in 2024.
• Research and development expenses decreased by 6.4% to $31.4 million in Q3 2025 and by 35.4% to $107.2 million for the nine months ended September 30, 2025, largely due to lower license-related payments.
• The VRK1 program (Sprint License Agreement) was discontinued, with termination effective August 15, 2025.
• The pimasertib program (Merck KGaA, Darmstadt, Germany agreement) was finalized for termination in September 2025.
• The EMA Marketing Authorization Application for tovorafenib was validated by Ipsen Pharma SAS on March 27, 2025.
• The DAY301 Phase 1a/b clinical trial cleared its first cohort in January 2025 and is currently in the dose escalation phase.
• An option repricing for certain outstanding stock options held by directors and employees was approved, effective October 7, 2025.

Sentiment

Score: 4

Explanation: While product revenue for OJEMDA showed strong growth, the company's net loss significantly widened compared to the prior year, largely due to the non-recurrence of a substantial license revenue payment from Ipsen in 2024. The discontinuation of two development programs (VRK1 and pimasertib) indicates pipeline adjustments, which could be seen as a negative for future growth prospects, though it may streamline focus. The company's cash position is deemed sufficient for 12 months, but the existence of an ATM program suggests a potential need for future capital. The EMA submission for tovorafenib is a positive step for international expansion. Given these mixed signals—strong commercial execution for OJEMDA but a deteriorating bottom line and pipeline adjustments—a 'Hold' recommendation is appropriate, awaiting clearer signs of sustained profitability and successful advancement of DAY301.

Positives

• Product revenue, net, for OJEMDA showed strong growth, increasing 91.9% to $38.5 million in Q3 2025 and 263.0% to $102.6 million for the nine months ended September 30, 2025.
• The European Medicines Agency (EMA) validated Ipsen Pharma SAS's Marketing Authorization Application for tovorafenib, indicating progress towards international commercialization.
• DAY301, a novel Antibody Drug Conjugate, successfully cleared its first cohort in the Phase 1a portion of its Phase 1a/b clinical trial and is advancing in dose escalation.
• OJEMDA was added to the National Comprehensive Cancer Network (NCCN) adult glioma treatment guidelines as a Category 2a recommended treatment option in June 2025.
• The company believes its cash, cash equivalents, and short-term investments of $451.6 million as of September 30, 2025, will be sufficient to satisfy capital requirements for at least twelve months.

Negatives

• Net loss significantly increased to $(19.7) million in Q3 2025 from a net income of $37.0 million in Q3 2024, and to $(86.0) million for the nine months ended September 30, 2025, from $(29.8) million in the prior year period.
• License revenue decreased substantially due to the non-recurrence of a large upfront payment from the Ipsen License Agreement in the prior year.
• The VRK1 program was discontinued, and the pimasertib program was closed, reducing the company's development pipeline.
• Cash and cash equivalents decreased from $124.968 million at December 31, 2024, to $43.277 million at September 30, 2025.
• Accumulated deficit increased to $(640.1) million as of September 30, 2025.

Risks

• The company is a commercial-stage biopharmaceutical company with a limited operating history, making it difficult for investors to evaluate its current business and likelihood of success.
• The company has incurred significant net losses since its inception and expects to incur continued losses, potentially never achieving or maintaining profitability.
• Near-term revenues are highly dependent on the successful commercialization of OJEMDA, which may not be commercially successful, adversely affecting business and stock price.
• Additional capital may be required to finance operations; inability to raise capital on acceptable terms could force delays, reductions, or elimination of research or product development programs.
• Clinical trials are expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes; earlier results may not be predictive of future trials.
• The company may rely on data from investigator-initiated studies, over which it does not control trial operations or reporting of results.
• The development and commercialization of pharmaceutical products are subject to extensive regulation, and marketing authorizations for DAY301 or future product candidates may not be obtained timely or at all.
• The manufacture of pharmaceutical products is complex, and third-party manufacturers may encounter production difficulties, delaying or halting supply for clinical trials or commercial sale.
• Future success depends on the ability to retain executive officers and key employees and to attract, retain, and motivate qualified personnel.
• The company will need to grow the size and capabilities of its organization, which may lead to difficulties in managing this growth.
• Inability to obtain and maintain patent protection or other necessary rights, or insufficient scope of protection, could allow competitors to commercialize similar products.
• Safety risks or other side effects associated with OJEMDA, DAY301, or future products could delay or preclude approval, cause suspension/discontinuation of trials, limit use, or result in negative consequences post-marketing authorization.
• Market opportunities for approved products may be limited to certain smaller patient subsets and may be smaller than estimated.
• OJEMDA and DAY301 may not achieve adequate market acceptance among physicians, healthcare professionals, patients, or payors.
• Approved products may become subject to unfavorable third-party coverage and reimbursement practices, as well as price restrictions.
• The business entails a significant risk of product liability, and insufficient insurance coverage could have an adverse effect.
• FDA expedited programs may not lead to faster development, regulatory review, or approval of product candidates.
• The accelerated approval pathway may be unavailable or, if available, may not lead to faster outcomes, and approval may be withdrawn.
• The company may not be able to obtain or maintain orphan drug designation or exclusivity for its product candidates.
• Failure to successfully develop, validate, obtain marketing authorization for, and commercialize any necessary companion diagnostic tests could prevent full commercial potential.
• Ongoing regulation and post-approval restrictions may limit how products are manufactured and marketed, requiring substantial resources.
• Failure to comply with post-marketing requirements could lead to substantial penalties, including withdrawal of products from the market.
• Failure to obtain marketing authorization in foreign jurisdictions would prevent products from being marketed there.
• Relationships with customers and third-party payors are subject to anti-kickback, fraud and abuse, transparency, health privacy, and other healthcare laws and regulations, exposing the company to significant penalties.
• Existing, recently enacted, and future legislation may increase the difficulty and cost of obtaining marketing authorization and decrease prices.
• Disruptions at the FDA may slow the time necessary for new products to be reviewed and/or approved.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• The company is subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, with serious consequences for violations.
• Limited experience as a commercial company means sales, marketing, and distribution of approved products may be unsuccessful or less successful than anticipated.
• Reliance on third parties to conduct clinical trials and perform research; failure to carry out duties, comply with regulations, or meet deadlines could delay programs or increase costs.
• Reliance on a limited number of suppliers for raw materials; disruptions could result in delays.
• The Ipsen License Agreement is important; Ipsen's failure to fulfill obligations or termination of the agreement could delay or prevent commercialization outside the U.S.
• Collaborations with third parties for development and commercialization may not be successful.
• Loss of any large customer, or cancellation/delay of a significant purchase, could reduce net sales.
• Employees, clinical trial investigators, CROs, CMOs, consultants, vendors, and commercial partners may engage in misconduct or improper activities.
• Compromised security measures, IT system failures, or security breaches could disrupt development programs, compromise sensitive information, or expose the company to liability.
• Subject to stringent and changing laws, regulations, and standards related to privacy, data protection, and data security.
• Investors' expectations regarding environmental, social, and governance (ESG) factors may impose additional costs and new risks.
• Natural disasters could adversely affect the business, and business continuity plans may be inadequate.
• Changes in tax laws or regulations applied adversely could have a material adverse effect.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• Strategic transactions could impact liquidity, increase expenses, and distract management.
• Patent terms may be inadequate to protect the competitive position for an adequate amount of time.
• Claims challenging the inventorship or ownership of patents and other intellectual property.
• Patent protection and prosecution for some product candidates may be dependent on third parties.
• Intellectual property discovered through government-funded programs may be subject to federal regulations, such as march-in rights.
• Geo-political actions could increase uncertainties and costs surrounding patent prosecution or maintenance.
• Inability to protect intellectual property rights throughout the world.

Future Outlook

The company expects research and development expenses to increase for the foreseeable future as product candidates advance through clinical trials, efforts expand, and additional candidates are acquired or developed. Significant expenses related to product manufacturing, marketing, sales, and distribution of OJEMDA and DAY301 (if approved) are also anticipated. Selling, general and administrative expenses are expected to remain relatively consistent in the near-term. The company believes its current liquidity of $451.6 million in cash, cash equivalents, and short-term investments as of September 30, 2025, will be sufficient to satisfy capital requirements for at least twelve months after the filing date. Enrollment for the FIREFLY-2 trial is expected to be completed in the first half of 2026. The company anticipates that tariffs may increase the cost of its active pharmaceutical ingredient (API) in the future and will continue to monitor the impact of the One Big Beautiful Bill Act. The financial impact of the recently approved option repricing is currently being evaluated and cannot be reasonably estimated at this time.

Management Comments

• "At Day One, we aim to identify and develop breakthrough medicines with the goal of improving the outcomes and life trajectories of patients of any age facing serious diseases – starting from Day One."
• "Our search & development strategy enables us to find, acquire, and develop potential bestor first-in-class programs with the goal of introducing new medicines that will make a real difference in the treatment of children and adults."
• "We believe our business development capabilities combined with our extensive experience in oncology drug development and deep ties within the research and patient advocacy communities, particularly within the pediatric setting, positions us to be a leader in identifying, acquiring and developing therapies for patients of all ages."
• "We believe our cash, cash equivalents and short-term investments will be sufficient to satisfy our capital requirements through at least twelve months after the date that this Quarterly Report is filed."

Industry Context

The company operates in the highly competitive and rapidly evolving biopharmaceutical industry, particularly in oncology and targeted therapeutics for genomically-defined cancers. It faces competition from major multinational pharmaceutical companies, established biotechnology firms, and emerging companies, many of which possess greater financial resources and experience. Key competitors in the BRAF inhibitor space include Genentech (Zelboraf), Novartis (Tafinlar, Mekinist), Pfizer (Braftovi, Mektovi), AstraZeneca (Koselugo), and SpringWorks (Gomekli), with several next-generation BRAF inhibitors also in clinical development. For PTK7-targeted ADCs, competitors include Sichuan Kelun Pharmaceutical Research Institute (SKB51) and Eli Lilly and Company (LY4175408), with preclinical candidates from Whitehawks, IDEAYA, and Biocytogens. The regulatory landscape is dynamic, with FDA initiatives like Project Optimus and Project FrontRunner, and legislative changes such as the Inflation Reduction Act, impacting drug development, pricing, and reimbursement. Geopolitical factors, including U.S. tariffs on Chinese imports and potential legislation like the BioSecure Act, pose risks to supply chains and manufacturing costs.

Comparison to Industry Standards

• OJEMDA's overall response rate (ORR) of 52.6% (95% CI: 40.8 64.2) and median duration of response of 18.0 months (95% CI: 12.0, 22.8) from the FIREFLY-1 trial are key efficacy metrics for relapsed or refractory pLGG.
• OJEMDA is positioned as the only systemic therapy for pLGG offering once-weekly dosing, which could be a competitive advantage.
• Novartis' dabrafenib in combination with trametinib is fully approved for BRAF V600E pLGG in pediatric patients 1 year and older requiring initial systemic therapy, directly competing with OJEMDA's ongoing FIREFLY-2 trial for front-line therapy.
• The discontinuation of Genmab A/S's PTK7-targeted ADC (PRO1107) due to benefit-risk balance highlights the challenges in ADC development, potentially impacting the competitive landscape for DAY301.
• The inclusion of tovorafenib in the NCCN adult glioma treatment guidelines as a Category 2a recommended treatment option signifies positive recognition within the medical community.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not presently a party to any material legal proceedings.

Related Party Transactions

• The Takeda Asset Agreement was entered into with Millennium Pharmaceuticals, Inc., an affiliate of Takeda Pharmaceutical Company Limited, which is a related party.

Stakeholder Impact

• Shareholders face potential dilution from future equity financings (ATM program) and stock price volatility, but also potential long-term value from successful product commercialization. The option repricing aims to retain key personnel, which could benefit long-term shareholder value.
• Employees benefit from the option repricing, which aims to retain and motivate them. Increased R&D and commercialization efforts may lead to hiring opportunities.
• Customers (patients and physicians) benefit from OJEMDA as a new systemic therapy option for pLGG. DAY301 is in early clinical development, offering future potential. The discontinuation of pimasertib and VRK1 programs means fewer potential future therapies from the company's pipeline.
• Suppliers and Contract Manufacturing Organizations (CMOs) continue to be relied upon, but face risks of disruption and increased costs due to factors like tariffs and geopolitical events.
• Creditors may view the company's accumulated deficit and ongoing losses as indicators of continued reliance on equity financing rather than debt for capital needs.

Next Steps

• Continue the commercial launch of OJEMDA in the United States.
• Complete enrollment of the pivotal Phase 3 FIREFLY-2 trial in the first half of 2026.
• Continue the dose escalation phase of the DAY301 Phase 1a/b clinical trial.
• Ipsen Pharma SAS will pursue marketing authorization for tovorafenib in Europe following EMA validation.
• Evaluate the financial impact of the recently approved option repricing for directors and employees.
• Monitor the ongoing impact of the One Big Beautiful Bill Act on the company's business.
• Explore diversifying sourcing and qualifying alternate domestic suppliers to mitigate future tariff risks on API costs.

Key Dates

Recommendation

The company demonstrated robust product revenue growth for OJEMDA, indicating successful initial commercialization. However, this was overshadowed by a substantial increase in net loss, primarily due to the non-recurrence of a significant license revenue payment from the prior year and ongoing R&D expenses. The discontinuation of two development programs (VRK1 and pimasertib) suggests a strategic refocusing, which could be positive for resource allocation but also reduces pipeline diversity. While the company has sufficient liquidity for the next 12 months, the presence of an ATM offering indicates a potential need for future capital. The EMA submission for tovorafenib is a positive step for international expansion. Given these mixed signals—strong commercial execution for OJEMDA but a deteriorating bottom line and pipeline adjustments—a "Hold" recommendation is appropriate, awaiting clearer signs of sustained profitability and successful advancement of DAY301.

Keywords

Biopharmaceuticals, Oncology, Pediatric Low-Grade Glioma, pLGG, BRAF fusion, BRAF V600 mutation, RAF kinase inhibitor, OJEMDA, tovorafenib, Antibody Drug Conjugate, ADC, DAY301, PTK7, Clinical Trials, FDA approval, EMA, Commercialization, Drug Development, Financial Results, Q3 2025, SEC Filing, 10-Q